Back to article: Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer

FIGURE 1: Multiple mechanisms of DMTi potentiation of anti-tumor immuni-ty. First, DMTi treatment up-regulates baseline MHC-I expression and MHC-I expression in response to IFN-γ, thereby enhancing antigen presentation capacity and cytotoxic CD8+ T cell activation. Second, DMTi treatment increases Cxcr3 chemokine (i.e., Cxcl9, Cxcl10, Cxcl11) expression, thereby enhancing T cell trafficking to the tumor microenvironment. Third, DMTi treatment activates NFκB signaling, presumably through ERV dsRNA expression, initiating an innate immune response. Each of these mechanisms in toto likely contribute to enhanced response to ICI therapy.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.